CINN‑101
Hereditary Transthyretin Amyloidosis
Phase 1/2aActive
Key Facts
About Cinnagen
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profileHereditary Transthyretin Amyloidosis
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profile